Providing inspiration, expertise, resources and guidance to set up a multidisciplinary center in your healthcare setting.
This site is intended for healthcare professionals only.

Privacy policy

« Home

This is the privacy notice (“notice”, “policy”) for the website which is run and provided by Springer Healthcare Ltd, The Campus, 4 Crinan Street, London N1 9XW; email [shmarketing@springer.com (we, us and our).

We will only use the personal data gathered over this website as set out in this policy. Below you will find information on how we use your personal data, for which purposes your personal data is used, with whom it is shared and what control and information rights you may have.

I.  Summary of our processing activities

The following summary provides you with a quick overview of the processing activities that are undertaken on our website. You will find more detailed information under the indicated sections below.

  • When you visit our website for informational reasons without setting up an account, only limited personal data will be processed to provide you with access to the website itself (see section III).
  • In case you register for one of our services or subscribe to receive communications, further personal data will be processed in the scope of such services (see section IV).
  • Furthermore, your personal data may be used to provide you with relevant advertising for related medical education (see section IV) and for statistical analysis that helps us to improve our website (see section V). Additionally, we improve your website experience with third party content (see section VI).
  • Your personal data may be disclosed to third parties (see section VII) that might be located outside your country of residence; potentially, different data protection standards may apply (see section VIII).
  • We have implemented appropriate safeguards to secure your personal data (see section IX) and retain your personal data only as long as necessary (see section X).
  • Under the legislation applicable to you, you may be entitled to exercise certain rights with regard to the processing of your personal data (see section XI).

II. Definitions

  • Personal data: means any information relating to a natural person who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, or an online identifier.
  • Processing: means any operation which is performed on personal data, such as collection, recording, organization, structuring, storage, adaptation or any kind of disclosure or other use.

III. Informational use of the website

When you visit our website for informational reasons, i.e. without registering for any of our provided services listed under IV and without providing us with personal data in any other form, we may automatically collect additional information about you which will contain personal data only in limited cases and which is automatically recognized by our server, such as:

  • the website from which you have been directed to our site from
  • the date and time of your requests
  • your device type, screen resolution and browser version
  • your internet service provider
  • information on your operating system, including language settings

We use such information only to assist us in providing an effective service (e.g. to adapt our website to the needs of your device or to allow you to log in to our website), and to collect broad demographic information for anonymized, aggregated use.

The personal data automatically collected is necessary for us to provide the website, Article 6 sec. 1 sent. 1 lit. b GDPR, and for our legitimate interest to guarantee the website’s stability and security, Article 6 sec. 1 sent. 1 lit. f GDPR.

IV. Registration for our services

1. Communicating with us

Our websites offer medical news and educational content. In order to access the aforementioned content, you may have to submit your contact information. With regard to the submission of your contact details and its subsequent use, we may process:

  • your email address;
  • your specialty and main area of work;
  • your National Provider Identifier (NPI) number or other relevant prescribing numbers;
  • Information (such as your name) that is provided through contact forms and email to us; or
  • Communications sent by you (e.g. via e-mail or website communication forms).

We will process the personal data you provide to:

  • Provide you with the services and information offered through the website or which you request
  • Communicate with you regarding your request

For this, the legal basis is Article 6 sec. 1 sent. 1 lit. b GDPR

The use of your personal data for behavioral advertising and profiling is done for the legitimate interest to improve your experience while using the website, Article 6 sec. 1 sent. 1 lit. f GDPR.

We use the personal data and contact data you provide by sign-up or registration to inform you directly about medical education programs and websites. 

The use of your personal data for directly advertising related products and services is a legitimate interest for us as a provider of this website, Article 6 sec. 1 sent. 1 lit. f GDPR.

Affiliated companies of Springer Healthcare Ltd are based in countries outside of the EU which may not provide the same level of data protection as countries in the EU.

You can object to the use of your personal data for direct marketing at any time. We will then refrain from any processing to the extent it is related to such purposes. You can inform us about your objection by contacting us at Springer Healthcare Ltd, The Campus, 4 Crinan Street, London N1 9XW email [email]

2. Access to sponsored content

Our website offers microsites providing access to sponsored content, e.g. to congress videos. To be able to access the videos you need to register providing the data:

  • your name
  • your address
  • your degree and a speciality description
  • your National Provider Identifier (NPI) number or other relevant prescribing numbers

We will process the personal data you provide to:

  • check your eligibility for access to the content; where content is restricted to specific professional groups this is clearly stated in the registration form, 
  • provide you with the services and information offered on the microsite,
  • communicate with you regarding your request,
  • fulfill our legal obligations regarding any mandatory reporting e.g. if access to the content is subject to ToV reporting under the US Sunshine Act of 2021.

For this, the legal basis is Article 6 sec. 1 sent. 1 lit. b GDPR

V. Analysis

1. General information about the analysis

For our statistical analyses, we use web analysis services that collect data on the use of this site and our apps.

The analysis services collect information such as:

  • Information on the device and browser (device type, operating system, browser version);
  • IP address;
  • Websites viewed, URL click stream (order in which the pages were viewed);
  • Geographical location;
  • Date and time of the website visit;
  • Reference page, application, or service;

We only use the information provided by the providers to determine the most useful information for you and to improve and optimize our website and apps. The information collected with the help of the analysis services is not linked to personal data.

Depending on the provider, the data generated about your use of our website and apps may be stored in a country outside the European Economic Area (EEA) and processed there, e.g. the United States. Further information on the potential risks of cross-border data transfers can be found under VIII. The analysis services only collect the IP address that is assigned to you when you visit this website, but not your name or other identifiers. The provider uses this information to evaluate your use of the website and apps, to compile reports on website usage and to offer us other services relating to the use of the website and apps and the internet.

The legal basis for this processing is Art. 6 Paragraph 1 Clause 1 lit. f GDPR. The processing is based on our legitimate interest in evaluating the data traffic on our website and in our apps to increase your user experience and to generally optimize the website and apps.

2. Google Analytics / Google Tag Manager / Big Query

We use Google Analytics, a web analytics service provided by Google Ireland Limited, Gordon House, Barrow Street, Dublin 4, Ireland (“Google”). The cookie set by Google Analytics on your device causes your web browser to transmit corresponding information to Google each time our website is called up. For example, Google Analytics collects data about the website from which a data subject has accessed a website (so-called referrer URL), which subpages of the website have been accessed or how often and for how long a subpage has been viewed. On our behalf Google will use the information generated by the cookie for the purpose of evaluating your use of the website, compiling reports on website activity and providing other services relating to website activity and internet activity in connection with the use of the website and according to your consent preferences.

The processing affects the following data categories:

  • IP addresses 
  • Online identifiers (including cookie identifiers) 
  • Device identifiers 
  • Technical characteristics of users (e.g., browser type and version, device type, operating system) 
  • Measurement of user behavior (e.g., views of individual pages / content, views of content from different areas, session duration / dwell time, bounce rate 
  • Use of individual website functionalities (e.g. timetable information, search queries, downloads) 
  • Referral URL

We use the addition “_gat._anonymizeIp” for web analysis via Google Analytics. By means of this add-on, your IP address is shortened and anonymized by Google before transmission to the USA if our website is accessed from a member state of the European Union or the European Economic Area. Only in exceptional cases will the full IP address be transmitted to a Google server in the USA and shortened there.

The legal basis for the data transfer is Article 28 GDPR in conjunction with the data processing agreement. The transfer of your personal data is subject to your consent according to Article 6 sec. 1 sent. 1 lit. a GDPR. You can consent to the processing of your data by Google Analytics using our Consent Manager, prevent the collection of your data or revoke consent once given. For revocation, call up the cookie settings again at the bottom of our website.

The information processed by Google about your use of this website may be transmitted to a Google server outside the EEA and processed there. The cross-border transfer is safeguarded by the Standard Contractual Clauses 2021. 

Your personal data will be anonymized by Google 14 months after your last activity, unless there is a legal obligation to retain it.

You may refuse the use of cookies by selecting the appropriate settings on your browser or by amending your preferences. In addition to that you may prevent the collection of the information generated by the cookie about your use of the website (including your IP address) and the processing of this data by Google if you download and install the browser plug-in available at the following link: http://tools.google.com/dlpage/gaoptout. You can access the Google Analytics privacy policy here.

The legal basis to process your data in this instance is Article 6 sec. 1 sent. 1 lit. f GDPR, our legitimate interest to improve and increase the use of our website as well as your interest in discovering content that is relevant to you. We will retain the data for 14 months, unless longer retention is legally required or allowed.

VI. Third party content and social media plug-ins

You can view a full list of third party content and social media plug-ins in use on this/these website(s) by selecting “Manage cookies/Do not share or sell my data” in the website footer.

Links to third party websites

This website may contain links to third party websites. We are not responsible for the content and the data collection on respective third party websites; please check the privacy policy of respective websites for information of respective websites’ data processing activities.

VII. Information sharing

Your personal data will only be disclosed to a third party to the extent necessary to fulfill our contractual relationship. Legal basis for the transfer of your personal data is Article 6 sec. 1 sent. 1 lit. b and f GDPR and represents our legitimate interest to implement our general terms and conditions of business or any other agreements concluded with you.

Some of the recipients mentioned above reside outside the EEA. For further information about cross border transfer in general and transfers outside of the EEA see VIII.

We may disclose anonymous aggregate statistics about users of the website in order to describe our services to prospective partners, advertisers and other reputable third parties and for other lawful purposes, but these statistics will include no personal data.

In the event that we undergo re-organisation or are sold to a third party, any personal data we hold about you may be transferred to that re-organized entity or third party in compliance with applicable law.

We may disclose your personal data if legally entitled or required to do so (for example if required by law or by a court order).

VIII. Cross border data transfers

Within the scope of our information sharing activities set out above, your personal data may be transferred to other countries (including countries outside the EEA) which may have different data protection standards from your country of residence. Please note that data processed in a foreign country may be subject to foreign laws and accessible to foreign governments, courts, law enforcement, and regulatory agencies. However, we will endeavor to take reasonable measures to maintain an adequate level of data protection when sharing your personal data with such countries.

In the case of a transfer to a country outside of the EEA, this transfer is safeguarded by EU Standard Contractual Clauses. You can find further information about the aforementioned safeguards under:
https://ec.europa.eu/info/law/law-topic/data-protection_en
or by contacting the Data Protection Team at dataprotection@springernature.com.

IX. Security

We have reasonable state of the art security measures in place to protect against the loss, misuse and alteration of personal data under our control. For example, our security and privacy policies are periodically reviewed and enhanced as necessary and only authorized personnel have access to personal data. Whilst we cannot ensure or guarantee that loss, misuse or alteration of information will never occur, we use all reasonable efforts to prevent it.

You should bear in mind that submission of information over the internet is never entirely secure. We cannot guarantee the security of information you submit via our website whilst it is in transit over the internet and any such submission is at your own risk.

X. Data retention

We strive to keep our processing activities with respect to your personal data as limited as possible. In the absence of specific retention periods set out in this policy, your personal data will be retained only for as long as we need it to fulfill the purpose for which we have collected it and, if applicable, as long as required by statutory retention requirements.

XI. Your rights

Under the legislation applicable to you, you may be entitled to exercise some or all of the following rights:

  1. require (i) information as to whether your personal data is retained and (ii) access to and/or duplicates of your personal data retained, including the purposes of the processing, the categories of personal data concerned, and the data recipients as well as potential retention periods;
  2. request rectification, removal or restriction of your personal data, e.g. because (i) it is incomplete or inaccurate, (ii) it is no longer needed for the purposes for which it was collected, or (iii) the consent on which the processing was based has been withdrawn;
  3. refuse to provide and – without impact to data processing activities that have taken place before such withdrawal – withdraw your consent to processing of your personal data at any time;
  4. object, on grounds relating to your particular situation, that your personal data shall be subject to a processing. In this case, please provide us with information about your particular situation. After the assessment of the facts presented by you we will either stop processing your personal data or present you our compelling legitimate grounds for an ongoing processing;
  5. take legal actions in relation to any potential breach of your rights regarding the processing of your personal data, as well as to lodge complaints before the competent data protection regulators;
  6. require (i) to receive the personal data concerning you, which you have provided to us, in a structured, commonly used and machine-readable format and (ii) to transmit those data to another controller without hindrance from our side; where technically feasible you shall have the right to have the personal data transmitted directly from us to another controller; and/or
  7. not to be subject to any automated decision making, including profiling (automatic decisions based on data processing by automatic means, for the purpose of assessing several personal aspects) which produce legal effects on you or affects you with similar significance.

You may (i) exercise the rights referred to above or (ii) pose any questions or (iii) make any complaints regarding our data processing by contacting us using the contact details set out below.

XII. Contacting us

Please submit any questions, concerns or comments you have about this privacy policy or any requests concerning your personal data by email to our Group Data Protection Officer. You can contact our Group Data Protection Officer via dataprotection@springernature.com.

The information you provide when contacting us will be processed to handle your request and will be erased when your request is completed. Alternatively, we will restrict the processing of the respective information in accordance with statutory retention requirements.

XIII. Amendments to this policy

We reserve the right to change this policy from time to time by updating our website respectively. Please visit the website regularly and check our respective current privacy policy. This policy was last updated on 4th April 2023

« Home

Site last updated: November 27, 2025

Springer Health+ IME logo

© 2026 Springer Health+ IME, part of Springer Nature Group

Funding

AstraZeneca and Alexion, AstraZeneca Rare Disease have provided an unrestricted educational grant towards this independent program.

Contact us

Email:

Springer Health+ IME
The Campus, 4 Crinan Street, London, N1 9XW, UK

Professor Marianna Fontana

Professor Marianna Fontana

University College London, UK

Marianna Fontana is Professor of Cardiology and is an Honorary Consultant Cardiologist at the Royal Free Hospital, University College London, where she is Director of the UCL Cardiac MRI unit, deputy Head of Center for Amyloidosis and deputy clinical lead of the National Amyloidosis Center.

Professor Fontana obtained her Medical degree (MD) and qualifications as a cardiologist at the University of Pisa in 2011. In 2012 she obtained a BHF Clinical Research Training Fellowship to undertake a PhD at UCL which focused on CMR in cardiac amyloidosis. In 2015 she became Senior Lecturer at UCL, Honorary Consultant Cardiologist and Director of the UCL CMR unit at the Royal Free Hospital, which she founded. In 2018 Prof Fontana was awarded an Intermediate Clinical Fellowship by the BHF. She was appointed deputy Head of Center for Amyloidosis and Acute Phase Proteins and deputy clinical lead of the National Amyloidosis Center in 2019. She took up the chair of Cardiology at UCL in 2020.

Professor Fontana’s major clinical and research interests are in the delivery of efficient and effective care for patients with amyloidosis, with a particular focus on new technologies: imaging and drugs. She lectures widely in the UK and internationally on amyloidosis, and organises many multi-professional educational events. She advises industry at all stages in the lifecycle of innovative products that can help improve the life-expectancy and quality of life of patients with amyloidosis. She is the recipient of numerous awards, including the Michael Davies Early Career Award in 2021 and the BHF Fellow of the year award in 2022. She has co-authored 252 peer reviewed publications with >18000 citations (h-index 71).

Disclosures
Marianna Fontana has received research grants from Pfizer, Eidos, Alnylam, and AstraZeneca. She has provided consultancy and/or been on Advisory boards for Attralus, Alnylam, Prothena, Akcea, Pfizer, Ionis, Intellia, Alexion, Novo Nordisk, Jennsen, AstraZeneca, Lexeo, and Cardior.

Dr Vaishali Sanchorawala

Dr Vaishali Sanchorawala

Boston University Chobanian & Avedisian School of Medicine, USA

Dr Sanchorawala’s research has led and defined the field in AL amyloidosis. She is recognized as one of the leading international experts and a key opinion leader in amyloidosis. With numerous publications and meeting presentations, she has been one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has been published in many peer-reviewed journals and has resulted in the evolution of the standard of care for these patients. She is currently heading many clinical trials in the treatment of AL amyloidosis. She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in amyloidosis, many of whom today play leadership roles in distinguished centers around the world.

Dr Sanchorawala serves on the executive steering committee of the Amyloidosis Research Consortium and as an associate editor of Amyloid, Journal of Protein Folding Disorders. She served as a secretary for the International Society of Amyloidosis from 2020-2022 and chair of the membership committee of the International Society of Amyloidosis from 2020-2022. She has been an invited speaker and session chair nationally and internationally.

Her influence extends beyond the groundbreaking and paradigm-shifting work in the field of amyloidosis. In addition to her scientific achievements and accolades, she is a beloved teacher, a caring mentor, and a compassionate physician with exceptional clinical acumen. She has an interest in working in charity organizations. She helps cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteer regularly at “Cradles to Crayons” charity, non-profit organization.

Disclosures
Vaishali Sanchorawala has received research support, acted as PI for Celgene, Millennium-Takeda, Janssen, Prothena, Sorrento, Karyopharm, Oncopeptide, Caelum, and Alexion.
She has provided consultancy and/or been on Advisory boards for Pfizer, Janssen, Attralus, GateBio, Proclara, Caelum, Abbvie, Regeneron, Protego, Pharmatrace, Telix, Prothena, AstraZeneca, and Naxcella.

Professor David Adams

Professor David Adams

Université Paris Saclay

David Adams is Professor of Neurology at the Université Paris Saclay, and Head of the Department of Neurology (2009-2023), Centre Hospitalier Universitaire Bicêtre, at Assistance Publique-Hôpitaux de Paris,. He was Head of the French National Reference Centre for Familial Amyloidotic Polyneuropathy (FAP) and other rare peripheral neuropathies from 2005 to 2021. His clinical expertise includes peripheral neuropathies, including FAP and other rare peripheral neuropathies, and he is particularly involved in the evaluation of the effects of disease-modifying therapies on neuropathy in patients with FAP in France including liver transplantation and innovative therapies including RNAi therapies and the neurological risks of domino liver transplantation.

Professor Adams has been an Advisory Board member for the International Symposium on FAP, and also organized the first European Congress on Hereditary ATTR Amyloidosis in 2015 in Paris, and the 1st European ATTR Amyloidosis Meeting for Patients and Doctors in 2017 in Paris. He has been a board member of the Peripheral Nerve Society and the European Academy of Neurology Scientific Panel Neuropathies and Président of the French speaking of Peripheral neuropathies ((2019-2021). He was Principal Investigator in many multicentric clinical trials for FAP (AATRv-PN) including APOLLO-A, HELIOS-A.

Disclosures
David Adams has received consultancy fees from Alnylam and AstraZeneca.

Inés Losada

Inés Losada

Internal medicine specialist Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain

Dra. Inés Losada is one of the coordinators of the multidisciplinary unit of ATTR in Son Llàtzer University Hospital.

Inés Losada participated in a company sponsored speaker bureau for Alnylam, Pfizer, and Akcea.

Mrs Christine Chiti

Mrs Christine Chiti

Clinical TTR nurse specialist, National Amyloidosis Centre, Royal Free Hospital, London, UK

Christine Chiti, RGN, Renal and ATTR Specialist Nurse, is currently providing comprehensive services to a wide variety of patients with ATTR Amyloidosis in the National Amyloidosis Centre. She has embarked on a new journey as a TTR specialist nurse in the National Amyloidosis Centre. She graduated as a Registered General Nurse in August 2000 with a Diploma in Nursing from Kitwe Central Hospital, Zambia.

Chiti has almost 24 years of nursing experience and worked in paediatrics and paediatric critical care, trauma, and neurology at Royal National Orthopaedic hospital, Fresenius dialysis Centres and Bart’s hospital. These posts have afforded her the opportunity to develop a well-rounded skill set with a multidisciplinary team. She firmly believes that a holistic approach is the effective way in providing quality care to patients with long term conditions.

Disclosures
Christine Chiti has participated in company sponsored speaker bureaus with Alnylam Therapeutics, Pfizer, and Astra Zeneca.

Dr Paolo Milani

Dr Paolo Milani

Assistant Professor, University of Pavia, Italy

Paolo Milani completed his medical training at the University of Pavia, Italy, where he later specialized in internal medicine and completed further qualifications in experimental medicine (PhD). During his PhD training he held a research fellowship role in hematology at the Mayo Clinic in Rochester, Minnesota, USA.

He is working as a clinician at the Amyloidosis Research and Treatment Center in Pavia, Italy and as an Assistant Professor in Clinical Chemistry at the University of Pavia. He is a member of a number of local and international scientific societies, including the Italian Society for Amyloidosis (currently Treasurer) and the International Society of Amyloidosis.

Dr Milani also serves as a reviewer for multiple internationally recognized journals and has authored over 110 publications focusing on the outcome prediction, treatment approaches, and diagnosis of cardiac amyloidosis.

Financial disclosures
Paolo Milani has received honoraria or consultation fees from Pfizer, Jansen, Siemens, and Prothena.

Eugenia Cisneros-Barroso

Eugenia Cisneros-Barroso

Postdoctoral researcher, Clinical research coordinator Fundación Instituto de Investigación Sanitaria Islas Baleares (IdISBa), Palma de Mallorca, Spain

Eugenia Cisneros-Barroso completed her Ph.D. in yeast cell signaling and molecular biology through the FPU program of the Spanish Ministry of Education and undertook an internship at the Scripps Research Institute. As a postdoctoral researcher at IdISBa, she contributed to the characterization of the DISC1-MICOS interaction and CHCHD10’s role in oxidative phosphorylation, publishing findings in EMBO Molecular Medicine. Later, shefocused on hereditary transthyretin amyloidosis (ATTRv) at Son Llàtzer University Hospital.

Despite challenges, she was awarded the ATTR-CM Competitive Research Grant for Young Investigators in 2021, securing $150,000 to develop the EXTRA Project, which aims to identify genetic modifiers of ATTR using exome sequencing. This grant allowed her to expand her team and mentor young scientists. Her research focuses on ATTR’s clinical characterization, genetic/epigenetic markers, and TTR regulatory mechanisms.

Currently, she collaborates on national and international projects, supervises three doctoral theses, and maintains an h-index of 9 with 571 citations. She is dedicated to advancing ATTRv research, with the EXTRA Project marking a significant step in her career as an independent investigator.

Grants research/support from Pfizer and Alnylam

Dr Roberta Mussinelli

Dr Roberta Mussinelli

Medical Consultant, Fondazione IRCCS Policlinico San Matteo

Dr Mussinelli graduated with honours at University of Pavia in 2011 and subsequently she became a specialist in Internal Medicine at the same University. She obtained the PhD diploma in Intern Medicine and Medical Therapy.

She has been working in the Amyloid Research and Treatment Center of Pavia since 2014, at first during her residency and then as a consultant from 2017. She is responsible for the cardiovascular evaluation of patients with amyloidosis. Her main research focus is the diagnosis and treatment of the different forms of cardiac amyloidosis and the management of the supportive therapy.

In 2017, she spent 6 months at the Amyloid Center at Boston University School of Medicine as a visiting researcher.

Since 2014 she is part of the International Society of Amyloidosis and a member of the Italian Society of Internal Medicine (SIMI) and American Society of Ecocardiography (ASE).

She is Sub-investigator for several ongoing clinical trials of novel drugs for the treatment of hereditary amyloidosis, wild-type TTR amyloidosis and AL amyloidosis. She has co-authored over 20 papers in international journals.

Financial disclosures
Roberta Mussinelli has participated in a company sponsored speaker bureau for Pfizer, SOBI and Alnylam.

Cristina Descals

Cristina Descals

Medical Doctor Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain

Cristina Descals Moll (MD) graduated in Medicine and Surgery from the University of Salamanca (1988-1994). I am specialized in Clinical Neurophysiology through the MIR program at Vall d’Hebron University Hospital (1996-2000). I have been an attending physician in the Neurology-Neurophysiology Service at Son Llàtzer University Hospital (HUSLL, Palma de Mallorca) since 2004. I am a member of the multidisciplinary team of the TTR Amyloidosis Unit (UM-TTR) at HUSLL since its establishment in 2012, participating in clinical trials, research projects, publications, and training.

Participated in a company sponsored speaker bureau for Pfizer and Alnylam.

Dr Laura Obici

Dr Laura Obici

Amyloidosis Research and Treatment Center, IRCCS Fondazione Policlinico San Matteo, Pavia

Laura Obici is Consultant at the Amyloidosis Research and Treatment Center, IRCCS Fondazione Policlinico San Matteo, Pavia. In February 2023 she was also appointed Head of the Rare Diseases Unit at Fondazione IRCCS Policlinico San Matteo. She was awarded her Medicine and Surgery degree with honors from the University of Pavia, Pavia, in 1994, and was later awarded a Master’s degree in molecular medicine and genetic epidemiology. In 2000, she became a specialist in internal medicine at the University of Pavia.

Dr Obici’s main research interests include the molecular mechanisms of systemic amyloidosis, the prognosis and therapy of systemic amyloidosis, and the genetic basis of hereditary amyloidosis and hereditary periodic fever syndromes.

Dr Obici was Secretary of the International Society for Amyloidosis from 2010 to 2014 and has participated as Principal Investigator/Co-investigator in twelve clinical trials of novel drugs for the treatment of hereditary amyloidosis and hereditary periodic fever syndromes. She has co-authored 195 peer-reviewed publications in international journals, including The New England Journal of Medicine, Amyloid and Journal of Molecular Biology.

Disclosures
Laura Obici has received honoraria and/or consultation fees from Pfizer, Alnylam, Astra Zeneca, Novo Nordisk, BridgeBio,and SOBI.

Juan González-Moreno

Juan González-Moreno

Internal medicine specialist, Hospital Universitario Son Llatzer, Palma, Spain

Dr Juan González-Moreno graduated in Medicine and Surgery from the Complutense University of Madrid (UCM) in 2008. Subsequently he trained in the speciality of Internal Medicine at the Hospital Universitario Son Llàtzer until 2014. He has also completed his training with postgraduate studies in systemic autoimmune diseases at the University of Barcelona (UB) and in minority diseases at the Francisco de Vitoria University in Madrid (UFV).

At research level Dr González-Moreno is currently PhD student in Biomedical and Evolutionary Biotechnology at the University of the Balearic Islands (UIB). He is also author or co-author of more than 50 indexed articles, mainly in the field of systemic autoimmune diseases and transthyretin amyloidosis.

He is currently an associate professor in the Department of Medicine at the University of the Balearic Islands (UIB).
In addition, Dr González-Moreno is a member of the Technical Committee of Minority Diseases of the Balearic Islands, as well as the Research Commission of the University Hospital Son Llátzer and Coordinator of the Multidisciplinary Unit of Transthyretin Amyloidosis of the University Hospital Son Llátzer.

Juan González-Moreno has received speaker fees from Pfizer, Alnylam, Akcea and Sobi, received travel expenses from Pfizer, Alnylam, Akcea and Sobi and research grants from Pfizer, Alnylam, Akcea and Sobi.

Prof. Dr. Sebastian Spethmann

Prof. Dr. Sebastian Spethmann

Associate Professor of Cardiology, Deutsches Herzzentrum der Charité - Berlin, Germany

Sebastian Spethmann is Deputy Director of the Department of Cardiology, Angiology and Intensive Care Medicine at the German Heart Centre at Charité and Co-Chair of the Amyloidosis Centre at Charité. As a specialist in cardiology, his clinical and academic work focuses on amyloidosis, heart failure, structural heart disease and innovative care models, including telemedicine and multidisciplinary collaboration. He has extensive experience in developing integrated care pathways and applying digital health tools to improve early detection and patient care for cardiovascular diseases.

Disclosures
Sebastian Spethmann has received honoraria/consultation fees from Alnylam Netherlands B.V. , AstraZeneca GmbH, Bristol Myers Squibb GmbH , Novartis Pharma GmbH, Pfizer Pharma GmbH, Bayer Vital GmbH and grants/research support from Pfizer Pharma GmbH.

Damian Heine Suñer

Damian Heine Suñer

Geneticist Hospital Universitari Son Espases, Palma, Illes Balears, Spain

Dr. Damian Heine Suñer received his PhD in genetics in 1995 from Rutgers University and the University of Medicine and Dentistry of New Jersey (UMDNJ) (USA).

From 1995 to 1999, Dr. Heine Suñer held a postdoctoral position in the laboratory of Dr. Santiago Rodríguez de Córdoba in Madrid (Spain) at the Centro de Investigaciones Biológicas (CIB) of the Consejo Superior de Investigaciones Científicas (CSIC).

In 1999 he started up the Molecular Genetics Laboratory in Mallorca within what is now the Molecular Diagnostics and Clinical Genetics Unit (UDMGC) at the Hospital Universitari Son Espases (HUSE). The UDMGC is the only clinical genetics service within the public health system of the Balearic Islands (IB-Salut) and performs more than 10,000 genetic analyses per year serving a population of 1,100,000 inhabitants.

He has contributed to implement the molecular genetic diagnosis of most of the UDMGC services portfolio, which covers more than 100 pathologies using both conventional molecular techniques and new generation techniques such as exome and whole genome sequencing or digital PCR.

Damian Heine Suñer has no disclosures.

Professor Mitsuharu Ueda

Professor Mitsuharu Ueda

Professor of Neurology, Graduate School of Medical Sciences, Kumamoto University, Japan.

Mitsuharu Ueda studied medicine followed by post-doctoral research at Kumamoto University School of Medicine, and Kumamoto University Graduate School of Medical Sciences in Japan, respectively.

In 2007 he was appointed as Assistant Professor at the Department of Diagnostic Medicine (Laboratory Medicine), at the Graduate School of Medical Sciences, Kumamoto University. Professor Ueda was Visiting Research Fellow at the department of Pathology and Laboratory Medicine at Indiana University-Purdue University Indianapolis in the USA between 2011-2012, and returned to Kumamoto to take up the post as Associate Professor of Neurology at the Graduate School of Medical Sciences, and was then appointed as Professor at the same institution in 2020 until the present day.

His areas of expertise are Primary Amyloidosis, Familial Transthyretin Amyloidosis, and Hereditary Transthyretin Amyloidosis.

Disclosures
Mitsuharu Ueda discloses grants/research support, honoraria and/or consultation fees from Alnylam and Pfizer.

Dr Yawara Kawano

Dr Yawara Kawano

Associate Director, Amyloidosis Center, Kumamoto University Hospital, Japan

Yawara Kawano graduated Kumamoto University School of Medicine in 2006. After 2 years of residency, Dr Kawano became a clinical fellow of Kumamoto University Hospital, Dept of Hematology. Dr Kawano worked as a post-doctoral research fellow in Dana-Farber Cancer Institute from 2013 to 2015. After returning to Kumamoto University Hospital, Dr Kawano has been serving as an assistant professor in the department of Hematology. He is also currently an associate director of the Amyloidosis Center of Kumamoto University Hospital, mainly engaged in diagnosis and therapy of AL amyloidosis.

Disclosures
Yawara Kawano discloses honoraria and/or consultation fees from Janssen Pharmaceutical, Bristol Myers Squibb, Sanofi, Ono Pharmaceutical, Takeda Pharmaceuticals, and Sebia.